Quick Takeaways: Why It Matters? Odacova’s emergence with a 9‑year longitudinal canine dataset (molecular, transcriptomic, metabolic, functional and immune endpoints) positions its bionutrition platform as a rare, biotech‑grade evidence play in the fast‑growing pet longevity sp...
Quick Takeaways: Why It Matters? Presenting full SLAB trial data for GF‑1004 (a SIRT6‑based gene therapy) positions Genflow to seek an animal‑health licensing or co‑development deal in a fast‑growing pet longevity/sarcopenia niche. If the results show meaningful improvements in...
Quick Takeaways: Why It Matters? Loyal’s completion of the RXE efficacy requirement for LOY‑003 means all three of its canine longevity candidates (LOY‑001, LOY‑002, LOY‑003) have now met the FDA’s efficacy bar under the Expanded Conditional Approval pathway, putting the compan...
Quick Takeaways Why It Matters? Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category. If LOY-002 secures conditional and then full approval, it could...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
